Kratom and its more potent semi-synthetic derivative 7-hydroxymitragynine (7-OH) have long existed in a regulatory gray area. The DEA's July proposal to temporarily place high-potency 7-OH products in Schedule I has sharpened a debate among addiction experts, clinicians, and advocates: nearly all agree the substances need guardrails, but they are divided on whether scheduling is the right tool.
Supporters of scheduling point to the risk of dependence and the need to act before another public-health crisis emerges. Critics note that Schedule I status could leave dependent users without access and facing criminal penalties, create an endless game of whack-a-mole with new synthetic variants, and make research harder. Georgetown addiction policy professor Regina LaBelle is quoted saying scheduling is often the only tool available, but questions whether it addresses underlying conditions.
Alternative approaches exist at the state level. Around two dozen states have enacted versions of the Kratom Consumer Protection Act, typically with age limits, but critics such as Shatterproof's Leah Kaufman say many are too weak. Utah and West Virginia are highlighted as stronger examples: Utah restricts sales to licensed specialty tobacco retailers, requires third-party testing and registration, and now bans anything other than pure leaf kratom. Such regimes require funding for labs, enforcement, and staff.
Pressure for federal action has grown after two University of Mississippi students died this month with kratom products found at the scene, though authorities have not said kratom contributed. The DEA's comment period ended Sept. 10 with nearly 36,000 submissions, and the agency has not finalized the rule. In the meantime, some states and localities have issued their own emergency bans.